Phase 1 clinical study data on NRL-1049 shows dose-proportional increase in exposure and favorable safety profile SAN DIEGO, Nov. 6, 2025 /PRNewswire/ — Neurelis, Inc., today announced it will present at the Alliance to Cure Cavernous Malformation (CCM) 21st International CCM Scientific…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
